Related Experiment Video

Updated: Jul 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Chao Wang1, Yujing Zhang2, Tingting Zhang1

  • 1The Affiliated Hospital of Qingdao University, Cancer Institute, Qingdao University, Qingdao 266071, Shandong, China; Qingdao Cancer Institute, Qingdao University, Qingdao 266071, Shandong, China.

International Journal of Biological Macromolecules
|October 15, 2023
PubMed

Insights

Dual-target inhibitors for the epidermal growth factor receptor (EGFR) show promise for overcoming drug resistance in cancers like NSCLC. These dual inhibitors offer improved efficacy and safety compared to single-target treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is implicated in various cancers, including lung, breast, and esophageal cancers.
  • EGFR single-target inhibitors have shown clinical efficacy but face challenges due to drug resistance from EGFR mutations.
  • Developing novel therapeutic strategies is crucial to overcome resistance and improve cancer treatment outcomes.

Purpose of the Study:

  • To review the development of dual-target inhibitors for EGFR in cancer therapy.
  • To explore the synergistic effects of EGFR family proteins with other anticancer targets.
  • To discuss the opportunities and challenges in the field of dual-target EGFR inhibitors.

Main Methods:

  • Comprehensive literature review on EGFR family proteins and their interactions.
  • Analysis of the development and clinical progression of EGFR single-target and dual-target inhibitors.
  • Examination of resistance mechanisms and strategies to overcome them.

Main Results:

  • EGFR dual-target inhibitors demonstrate potential for overcoming resistance associated with EGFR mutations.
  • These inhibitors offer advantages such as reduced risk of resistance, enhanced efficacy, lower dosage, and fewer adverse events.
  • Sequential development of dual-target inhibitors provides new therapeutic avenues for difficult-to-treat malignancies.

Conclusions:

  • EGFR dual-target inhibitors represent a promising advancement in cancer therapy, particularly for overcoming resistance.
  • Further research and development are needed to fully realize the potential of these compounds.
  • Dual-target inhibitors lay the foundation for future generations of more effective cancer treatments.
Keywords:
CancerCancer therapyDual-target inhibitorsEpidermal growth factor receptorTyrosine kinase inhibitors

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539